drugset / Trial / NCT06170723

A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants

NCT06170723

Phase 1 Completed 32 enrolled Celgene Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This 2-part study will evaluate the effect of coadministration of a Cytochrome P450, family 3, subfamily A (CYP3A) inhibitor, itraconazole (Part 1), and a high-fat/high-calorie meal and a modified gastric pH (Part 2), on the single dose drug levels of BMS-986368 in healthy participants.

Timeline

Start
2024-03-18
Primary completion
2024-05-25
Completion
2024-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986368 Unknown
Subject Famotidine Other / unclassified
Subject Itraconazole Small molecule

Indications

No indication recorded.